Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
- PMID: 34279572
- DOI: 10.1001/jama.2021.11768
Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Similar articles
-
Medicare Coverage of Aducanumab - Implications for State Budgets.N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20. N Engl J Med. 2021. PMID: 34797617 No abstract available.
-
Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.J Manag Care Spec Pharm. 2018 Dec;24(12):1230-1238. doi: 10.18553/jmcp.2018.24.12.1230. J Manag Care Spec Pharm. 2018. PMID: 30479199 Free PMC article.
-
Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.Ann Neurol. 2021 Sep;90(3):331-333. doi: 10.1002/ana.26167. Epub 2021 Aug 10. Ann Neurol. 2021. PMID: 34278596 No abstract available.
-
Aducanumab and the FDA - where are we now?Nat Rev Neurol. 2021 Mar;17(3):129-130. doi: 10.1038/s41582-020-00454-9. Nat Rev Neurol. 2021. PMID: 33442064 Review. No abstract available.
-
FDA Drug Approval and the Ethics of Desperation.JAMA Intern Med. 2021 Dec 1;181(12):1555-1556. doi: 10.1001/jamainternmed.2021.6045. JAMA Intern Med. 2021. PMID: 34694325 Free PMC article. Review. No abstract available.
Cited by
-
Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.Lancet Reg Health Am. 2023 Mar 1;20:100467. doi: 10.1016/j.lana.2023.100467. eCollection 2023 Apr. Lancet Reg Health Am. 2023. PMID: 36908502 Free PMC article. Review.
-
Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases.J Neuroinflammation. 2022 Sep 8;19(1):223. doi: 10.1186/s12974-022-02584-x. J Neuroinflammation. 2022. PMID: 36076238 Free PMC article. Review.
-
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.JAMA Neurol. 2022 May 1;79(5):478-487. doi: 10.1001/jamaneurol.2022.0315. JAMA Neurol. 2022. PMID: 35344024 Free PMC article.
-
Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology.J Neuroinflammation. 2022 Feb 7;19(1):35. doi: 10.1186/s12974-022-02393-2. J Neuroinflammation. 2022. PMID: 35130907 Free PMC article.
-
Recent update on the heterogeneity of the Alzheimer's disease spectrum.J Neural Transm (Vienna). 2022 Jan;129(1):1-24. doi: 10.1007/s00702-021-02449-2. Epub 2021 Dec 17. J Neural Transm (Vienna). 2022. PMID: 34919190 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical